Advanced Ovarian Cancer
Conditions
Keywords
Real-world evidence, Homologous recombination deficiency, breast cancer gene, breast cancer gene mutated, breast cancer gene wild type
Brief summary
This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
Detailed description
This is a United States (US) based multicenter, retrospective, observational cohort study with data abstracted from patient medical records. In this observational study, it is planned to include approximately 150 US female patients with newly diagnosed advanced ovarian cancer (AOC) who were tumor biomarker tested between first diagnosis with AOC and first prescription of 1L olaparib maintenance monotherapy as tumor breast cancer gene wild type (BRCAwt) with a known homologous recombination deficiency (HRD) status. This retrospective cohort study will include patients with first olaparib prescription between Jan 2017 and Dec 2021. All data collection will be retrospective. Data will be collected from the date of first olaparib prescription (index date) with a follow-up period of at least 18 months post index date.
Interventions
OTHERNone (Observational Study)
Not Applicable since observational study
Sponsors
Merck Sharp & Dohme LLC
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 130 Years
Healthy volunteers
No
Inclusion criteria
* Female adult, age ≥ 18 years * BRCAwt AOC diagnosed with any approved BRCA test * Has documented HRD status based on available test results * Received 1L olaparib maintenance monotherapy following platinum chemotherapy * Patients must have been treated with platinum-based chemotherapy at first-line
Exclusion criteria
* Received another poly adenosine diphosphate ribose polymerase (PARP) inhibitor or bevacizumab before or while prescribed olaparib * Participation in an interventional clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical and Demographics characteristics | At Index date - first olaparib prescription (Jan 2017 to Dec 2021) | Clinical and Demographic characteristics including disease/FIGO stage, histology and tumor grade at initial Ovarian Cancer diagnosis, cancer antigen 125 (CA-125) level, Eastern Cooperative Oncology Group (ECOG) or other performance status, number and type of chemotherapy cycles, cytoreductive/debulking surgery type and outcomes, and selected comorbidities at index date will be described. Summary statistics will be used to describe the Demographics and clinical characteristics. The outcome will be measured for HRD+ patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Real-world time to first subsequent treatment or death (rwTFST) | Jan 2017 to Jun 2023 | rwTFST is defined as the time from the index date (date of the first olaparib prescription) to the earliest of the date of death or commencement of first subsequent anticancer treatment. The outcome will be measured for HRD+ patients. |
| Real-world time to treatment discontinuation or death (rwTTD) | Jan 2017 to Jun 2023 | rwTTD is defined as the time from the index date to the earliest of the date of death or discontinuation of olaparib. The outcome will be measured for HRD+ patients. |
| Number of patients with clinical event of interest (CEI) | Jan 2017 to Jun 2023 | To summarize the real-world safety and tolerability profile based on pre-specified CEIs of 1L olaparib maintenance monotherapy in BRCAwt newly diagnosed AOC patients regardless of HRD status. |
Countries
United States
Outcome results
None listed